Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
July 26, 2023 at 01:16 am EDT
Share
Genomma Lab Internacional, S.A.B. de C.V. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was MXN 4,370.51 million compared to MXN 4,323.64 million a year ago. Net income was MXN 417.4 million compared to MXN 404.75 million a year ago.
For the six months, sales was MXN 8,548.73 million compared to MXN 8,338.45 million a year ago. Net income was MXN 775.4 million compared to MXN 743.93 million a year ago.
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Companyâs product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V. 
